Michele Anderson

Michele Anderson is the Chief Development Officer at Braveheart Bio, with over 25 years of experience in drug development and regulatory strategy. Her previous experience includes a leadership role at Biogen’s West Coast Hub (formerly HI-Bio), where she managed Regulatory Affairs, Pharmacovigilance, and Quality, and launched the Phase 3 global start-up for felzartamab. During her tenure at Gilead Sciences, Inc., she led the regulatory affairs aspects involved in the development and worldwide approvals of antiviral therapies for HCV and HBV. She also served as CDO at Assembly Biosciences, leading clinical development. Michele holds a B.S. in Biological Sciences from California Polytechnic State University, San Luis Obispo.

‍